It’s Not Enough to Kill the Bug

If you’ve been treated for Lyme disease or COVID-19 and still feel unwell months later — drained, foggy, achy, wired but exhausted, cold when no one around you is — you are not imagining it, and you have not failed your treatment. More and more, the immunology points to a hard truth: in many people, the lingering misery is no longer being caused by the infection at all. It’s being caused by the inflammation that infection left smoldering in the lining of the blood vessels.

This is one of the more important shifts in how we understand complex chronic illness, and a great deal of the science behind it comes from Dr. Bruce Patterson, a former Stanford virologist whose laboratory work places long COVID, chronic Lyme, and ME/CFS in the same family: immune-driven, vascular inflammatory conditions that linger after any active infection is gone.

I want to walk through what he found, why it explains so much of what we see in our patients, and where it fits into the careful, terrain-based way we practice here at Tree of Light Health.

Most care for these illnesses focuses, sensibly, on the organism. For Lyme that means antibiotics, antimicrobial herbs, and antiparasitics; for long COVID it has often meant antivirals. That work matters — lowering the pathogen burden is real and necessary.

But a large group of patients knock the infection down and still don’t get their lives back. The fatigue, the brain fog, the joint and muscle pain, the post-exertional crashes, the dizziness and palpitations and ringing ears all stay. For years that was waved away or blamed on the patient. Dr. Patterson’s research offers a cleaner explanation: the symptoms were never coming straight from the bug — they were coming from the body’s immune reaction to it. Take away the trigger but leave the inflammatory machinery running, and the machinery keeps the symptoms going.

“Chronic Lyme” and “long COVID” may have less to do with persistent infection than with persistent inflammation.

Dr. Patterson is a physician and molecular biologist who served as Director of Virology at Stanford University School of Medicine. Much of his early career was spent studying HIV and the CCR5 receptor — the doorway HIV uses to enter immune cells — work that helped shape modern antiretroviral strategy. When COVID-19 appeared, he recognized a familiar pattern of immune dysregulation and turned to it almost immediately. Through his diagnostics company IncellDx, and more recently HealthBio Therapeutics, his team has now studied and treated more than 12,000 patients with long COVID and related syndromes, publishing repeatedly along the way. That long fluency in the CCR5 pathway turned out to be the key that unlocked the mechanism.

In plain language, here is the chain of events his group has mapped out. Long after the active virus or bacteria is cleared, fragments remain — the SARS-CoV-2 spike (S1) protein in long COVID, and Borrelia cell-wall pieces in chronic Lyme. You don’t need a living, replicating organism for the immune system to keep reacting to debris like this.

Those fragments get carried inside a particular class of white blood cells — non-classical and intermediate CD16+ monocytes — whose job is to patrol the walls of your blood vessels. Loaded with foreign protein, these cells dodge their normal self-destruct program and survive far longer than they should. Studded with CCR5 and fractalkine receptors, they dock onto the endothelium, the delicate vessel lining, and set off what Patterson calls vascular endothelialitis. The inflamed lining then recruits platelets, which activate and release still more inflammatory signals — the now widely discussed microclot phenomenon. He describes this self-feeding loop as the monocyte–endothelial–platelet axis.

Seen this way, the seemingly random symptom list finally makes sense. Fatigue tracks closely with the inflammatory protein TNF-α. Brain fog, tinnitus, headaches, and that maddening hot-and-cold intolerance follow the abnormal widening of blood vessels driven by VEGF and IL-2. Racing heart and POTS-style dysautonomia appear when widespread vasodilation drops blood pressure and the heart speeds up to compensate. And post-exertional malaise worsens because exercise and stress mobilize the very monocytes driving the whole process. None of it requires the infection to still be active.

One of Dr. Patterson’s most practical contributions is a way to measure this inflammation rather than guess at it. Working with Radiance Diagnostics, his team built a cytokine and chemokine panel that produces a calculated Long Hauler Index — an immune “fingerprint” built largely from two ratios:

Because different chronic inflammatory conditions express different patterns, this panel helps separate long COVID from chronic Lyme from ME/CFS — illnesses that look almost identical from the outside but may call for different combinations of treatment. In his framework, signatures pointing toward Lyme include elevated IL-8 with high interferon-gamma, elevated IL-13 with high interferon-gamma, or a Long Hauler Index above 6 — findings that prompt a deeper tick-borne workup. For us, this is the difference between guessing and practicing genuine precision medicine.

The familiar Lyme and long COVID tools — doxycycline, rifampin, disulfiram, artemisinin, cryptolepis, and herbal anti-inflammatories like curcumin, boswellia, and andrographis — all do valuable work. But none of them directly blocks the CCR5/CCL5 axis that draws inflammatory monocytes into the tissues. That is the specific gap Dr. Patterson’s combination is meant to fill.

The two medications work in complementary ways. Maraviroc, a CCR5 antagonist, sits on the CCR5 receptor and blocks the CCL5 (RANTES) signal, halting inflammatory monocyte migration and helping shift those cells out of their inflamed state. Atorvastatin (or pravastatin) does something separate but reinforcing — it lowers fractalkine on the vessel wall, removing the docking sites those long-lived monocytes rely on and nudging them back toward normal cell death. Together they work both ends of the monocyte–endothelial–platelet axis.

Where the evidence stands

This is an emerging, investigational approach, and I want to be straight about that. Maraviroc is FDA-approved for HIV and atorvastatin for cholesterol; using them this way is off-label. The encouraging part is that the work has moved beyond anecdote: a peer-reviewed case series in Frontiers in Medicine (2023) documented improvement in both symptoms and objective biomarkers, and in 2025 HealthBio Therapeutics began an FDA Fast-Track, 252-patient, 32-week randomized, double-blind, placebo-controlled trial of maraviroc plus atorvastatin for long COVID. The same mechanism is now being explored for ME/CFS, chronic Lyme, and fibromyalgia. The choice between atorvastatin and pravastatin is individualized — pravastatin avoids competing with maraviroc’s metabolism, while atorvastatin crosses into the brain more readily and has pediatric safety data.

This is the heart of how we practice. I don’t see maraviroc as a magic bullet or a one-size protocol — Dr. Patterson himself rejects the word “protocol” in favor of individualized care, and so do we. I see CCL5-axis modulation as the missing half that finally lets terrain medicine finish the job.

In a complex case, a full plan usually unfolds in layers. First we stabilize the terrain — calming the nervous system, opening drainage, restoring the gut, supporting mitochondria and minerals, and addressing mold or CIRS where it’s present — so the body can tolerate deeper work. Then we lower the pathogen load with antimicrobial herbs, targeted antibiotics when warranted, EBOO ozone therapy, and, when appropriate, Q-REstrain by RGCC to silence specific remaining organisms. And then we quiet the vascular fire — which is where a CCR5 antagonist like maraviroc with a statin, or its natural counterpart below, comes in. We treat the pain and the vasculitis, not only the organism.

For a fuller picture of how we sequence these tools, see our terrain-based roadmap for chronic Lyme and our overview of advanced biologic therapies and immune balance.

Maraviroc has two real drawbacks — possible side effects, and cost. It can run upward of $500 a month and is generally not covered by insurance for this use. So we’re often asked whether the same inflammatory axis can be calmed using the body’s own biology.

It may be possible. TruDose™ PRP — precision-dosed, platelet-rich plasma made from your own blood — delivers a payload of hundreds of growth factors and signaling molecules whose net effect includes resolving chronic inflammation and recalibrating immune signaling. Among those effects appears to be the potential to help modulate CCL5 (RANTES), the very chemokine maraviroc targets, but using your own healing biology rather than a drug. Tree of Light Health is the only TruDose PRP provider in Georgia, and in complex cases we’ll often sequence EBOO to lower the pathogen load, then TruDose PRP to recalibrate the immune system. Whether the inflammatory half of your plan is best served by maraviroc, by TruDose PRP, or by a combination is exactly the kind of decision we make together, guided by your labs, your history, and how your body responds.

Good decisions start with good data. The cornerstone is the Long Hauler cytokine panel from Radiance Diagnostics — IL-2, IFN-γ, CCL4, IL-8, IL-13, TNF-α, IL-6, CD40L, and fractalkine — which generates the Long Hauler Index and tells us who is most likely to benefit from CCL5-axis therapy. We may add a CCL5 (RANTES) level, since elevations point to ongoing chemokine-driven immune recruitment. When the signature leans toward Lyme, we pursue a proper tick-borne workup — immunoblot, culture-enhanced PCR, or a Vibrant tick-borne panel. And because the immunosuppression of these illnesses can wake up old viruses, we check EBV and CMV by DNA PCR rather than antibody testing, since antibodies can’t tell us whether a chronic herpes-family virus is currently active.

Maraviroc is generally well tolerated, but it earns respect. Possible effects include dizziness or fatigue, stomach upset, rarely elevated liver enzymes, low blood pressure, and — uncommonly, in higher-risk patients — cardiovascular effects; statins carry their own liver-related cautions. That’s why, when this approach is used, we establish baseline labs including liver function and monitor on a regular schedule throughout. This is prescription therapy that belongs with a knowledgeable clinician, coordinated with the rest of your care — never something to source or self-dose.

Maybe the most important message in Dr. Patterson’s work is this: people are not permanently broken. When patients have been pounded with round after round of antibiotics that eventually stop working, it’s usually because no one ever addressed the chronic inflammation left behind. That inflammation is treatable. The vascular fire can be put out. And when it is — alongside honest attention to the underlying infection and the terrain that allowed it to take hold — energy, clarity, and quality of life can come back.

We must not only treat the pathogen. We must also treat the immune system it dysregulated.

Martin Van Lear, APRN, MSN, ABAAHP, FNP-C Owner & primary provider, Tree of Light Health · Board-certified in Family Medicine · A4M-certified
Trained directly with Dr. Dietrich Klinghardt & Dr. Kucera · The only TruDose™ PRP provider in Georgia